Post COVID-19 sequelae of the respiratory system. A single center experience reporting the compromise of the airway, alveolar and vascular components
Authors:
- Nousheen IqbalNINousheen Iqbal
- Iffat KhanumIKIffat Khanum
- Muhammad Ali Ibrahim KaziMKMuhammad Ali Ibrahim Kazi
- Syeda Urooj RiazSRSyeda Urooj Riaz
- Uzzam Ahmed KhawajaUKUzzam Ahmed Khawaja
- Safia AwanSASafia Awan
- Muhammad IrfanMIMuhammad Irfan
- Ali Bin Sarwar ZubairiAZAli Bin Sarwar Zubairi
- Javaid Ahmed KhanJKJavaid Ahmed Khan
Open Access
- 11 October 2022
- journal article
- research article
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 93 (3)
Abstract
The long-term sequelae of COVID-19 have now become more common and appreciable. The SARS-CoV-2 virus can cause a variety of infectious and non-infectious pulmonary complications. The purpose of this study is to raise awareness about post-COVID-19 pulmonary sequelae, both infectious and non-infectious, in this geographical area. A retrospective study was conducted from July 1st 2020 to December 20th 2020. A total of 1200 patients were evaluated, with 83 suffering from post-COVID-19 pulmonary complications. The patients' mean age was 62 years (IQR 55-69), with 63 (75.9%) being male. The most common co-morbid illnesses were hypertension (49, 59%) and diabetes (45, 54.2%). The majority of them (37, 44.6%) had severe COVID-19, followed by critical COVID-19 (33, 39.8%). There was no statistically significant difference in recurrence of respiratory symptoms or duration of current illness between non-severe, severe, and critical COVID-19 patients. Non-infectious complications were observed in the majority of patients (n=76, 91.5%), including organizing pneumonia/ground glass opacities in 71 (88%) patients, fibrosis in 44 (55%), pulmonary embolism in 10 (12.5%), pneumomediastinum in 6 (7.4%) and pneumothorax in 7 (8.6%). Infective complications (25, 30.1%) included aspergillus infection in 10 (12.0%) and bacterial infection in 5 (8.47%), with more gram-negative infections and one patient developing Mycobacterium tuberculosis. Post COVID-19 mortality was 11 (13.3%). The long-term pulmonary sequelae of COVID-19 are not rare. Cryptogenic organizing pneumonia, ground glass opacities, and fibrosis were common post-COVID-19 sequelae in our patients. This necessitates frequent close monitoring of these patients in order to initiate early appropriate management and prevent further morbidity and eventual mortality.Keywords
This publication has 32 references indexed in Scilit:
- The Unrecognized Threat of Secondary Bacterial Infections with COVID-19mBio, 2020
- Respiratory follow-up of patients with COVID-19 pneumoniaThorax, 2020
- Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction StrategiesPulmonary Medicine, 2020
- Persistent Symptoms in Patients After Acute COVID-19JAMA, 2020
- Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infectionThrombosis Research, 2020
- Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from IranMycopathologia, 2020
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19Thrombosis Research, 2020
- COVID‐19‐associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID‐19 pneumonia: An observational study from PakistanMycoses, 2020
- COVID-19 and tuberculosisJournal of Translational Internal Medicine, 2020
- COVID-19: is fibrosis the killer?Journal of Cell Communication and Signaling, 2020